The ruling follows Monday's launch of Actavis's generic version of Pulmicort after the court found that it did not infringe the drug's patent.
Under a 2008 agreement with AstraZeneca, Teva has exclusive rights to sell a generic version of Pulimcort. Teva paid AstraZeneca $260 million in 2012 in royalties.
You comment was recieved and soon will be published.
Thank you for posting your comment, which will be reviewed for publication.
Load more comments